Chemotherapeutic regimes involving alkylating agents, such as methylators and crosslinking nitrogen mustards, represent a major risk factor for acute myeloid leukaemia. A high frequency of microsatellite instability and evidence of MSH2 loss in alkylating chemotherapy-related acute myeloid leukaemia (t-AML) suggests that DNA mismatch repair (MMR) dysfunction may be an initiating event in disease evolution. Subsequent accumulation of secondary genetic changes as a result of DNA MMR loss may ultimately lead to the gross chromosomal abnormalities seen in t-AML. Homologous recombination repair (HRR) maintains chromosomal stability by the repair of DNA double-strand breaks, and is therefore a possible target for deregulation in MMR dysfunctional t-AML. In order to test this hypothesis Msh2-proficient and -deficient murine embryonic stem (ES) cells were used to examine the effects of MMR status and methylating agent treatment on cellular expression of DNA double-strand break repair genes. HRR gene expression was significantly deregulated in Msh2 null ES cell clones compared to wild-type clones. Furthermore, some Msh2 null clones expressed high levels of Rad51 specifically, a critical component of HRR. Such Rad51 superexpressing clones were also observed when expression was determined in monocytic myeloid cells differentiated from ES cells. A deregulated HRR phenotype could be partially recapitulated in MMRcompetent wild-type cells by treatment with the methylating agent, N-methyl-N-nitrosourea. Furthermore, treatment with melphalan, a leukaemogenic DNA crosslinking chemotherapy nitrogen mustard predicted to elicit HRR, selected against cells with deregulated HRR. These data suggest a t-AML mechanism whereby DNA MMR loss promotes the emergence of HRR gene superexpressing clones, with concomitant chromosomal instability. However, melphalan selection against clones with deregulated HRR suggests that persistence and expansion of unstable clones may require additional genetic alterations that promote cell survival.
Introduction
Therapy-related acute myeloid leukaemia (t-AML) is a late complication of chemotherapy and/or radiotherapy given for a primary disorder, usually a cancer, and represents upto 10% of all AML cases (Thirman and Larson, 1996) . Chemotherapeutic regimes involving high doses of one or more alkylating agent represent a major risk factor for t-AML (Davies, 2001) . t-AML that develops after alkylating agent chemotherapy is characterized by a relatively long latency period (2-10 years), and a complex karyotype often featuring loss or deletion of chromosome 5q and/or 7 (Pedersen-Bjergaard et al., 2002) . High-grade microsatellite instability in 30-80% of t-AML cases (Ben-Yehuda et al., 1996; Sheikhha et al., 2002; Casorelli et al., 2003; Worrillow et al., 2003) , and evidence of dysfunctional MSH2 (Zhu et al., 1999) , suggests that DNA MMR loss is also a characteristic feature of t-AML after alkylating agent therapy. A direct interaction between several leukaemogenic chemotherapeutic alkylating agents and DNA mismatch repair (MMR) suggests a mechanism whereby high-dose chemotherapy selects for haematopoietic stem cells with DNA MMR defects, and the subsequent accrual of secondary genetic alterations, including chromosomal instability, ultimately leading to leukaemogenesis (Davies, 2001) .
The majority of chemotherapeutic alkylating agents damage DNA either by methylation or DNA interstrand crosslink formation. Methylating agents, which include procarbazine, dacarbazine, and temozolomide, contain one structural methyl group that can form DNA monoadducts at the N7 and O 6 atoms of guanine, the N1 and N3 atoms of adenine and the N3 atom of cytosine (Beranek et al., 1980; Engelward et al., 1998) . Of these lesions, O 6 -methylguanine is generally considered to be the most cytotoxic (Bignami et al., 2000) . In contrast to the methylating agents, several other chemotherapy agents such as melphalan, cyclophosphamide, chlorambucil and mitomycin C, contain two structural alkyl groups that can attack opposing bases in complementary DNA strands creating crosslinks. Although interstrand crosslinking agents may also generate monoadducts, cytotoxicity is directly linked to the proportion of interstrand crosslinks formed (Chaney and Sancar, 1996) . Covalent bonding of bases in opposing strands of the DNA helix efficiently blocks replication during cell division, and can initiate the formation of potentially lethal or mutagenic DNA double-strand breaks.
Chemotherapeutic O 6 -guanine methylators represent the major group of agents that can evoke a DNA MMR-mediated cellular response (Karran et al., 2003) . In humans, the MutSa heterodimer, comprising MSH2 and MSH6, recognizes misincorporated thymine inserted opposite O 6 -methylguanine during DNA replication (Duckett et al., 1996) . Subsequent recruitment of MutLa (MLH1 and PMS2) facilitates degradation and resynthesis of the mispaired region in the daughter strand. In the MMR-mediated cell death model, futile cycles of attempted repair and resynthesis are postulated to lead to apoptosis, thus preventing survival of damaged cells (Karran et al., 2003) . Cells harbouring a DNA MMR defect display an increase in tolerance to the cytotoxic effects of methylating agents (Kat et al., 1993; Marra et al., 2001 ). As such, cells displaying a methylationtolerant phenotype conferred by MMR deficiency may be positively selected from a MMR-proficient population by exposure to O 6 -guanine methylating agent (Humbert et al., 1999) .
Loss of DNA MMR may be induced in cells in vitro by treatment with O 6 -guanine methylating agents. Indeed, the high rate of microsatellite instability in t-AML suggests that the selection of MMR-negative clones by methylating agents may occur in vivo. Moreover, multiple cycles of chemotherapy may select a MMR-deficient clone susceptible to the accrual of genetic alterations secondary to a MMR defect that may ultimately modify apoptosis, cell growth or other DNA repair pathways. The gross chromosomal abnormalities seen in t-AML, particularly in microsatellite unstable t-AML, suggest homologous recombination repair (HRR) as one possible cellular pathway that may be affected by DNA MMR loss.
HRR maintains chromosomal stability by the accurate repair of DNA double-strand breaks. Activation of ATM protein kinase in response to DNA double-strand breaks induces phosphorylation of a number of proteins required directly or indirectly for DNA repair, including NBS1, BRCA1 and c-ABL (Valerie and Povirk, 2003) . NBS1 is a component of the MRE11/RAD50/NBS1 (MRN) complex that is thought to facilitate DNA unwinding and the resection of DNA ends (Trujillo et al., 1998; Paull and Gellert, 1999) . In vitro studies in mammalian cells indicate that the MRN complex associates on DNA double-strand breaks in an ATMindependent manner and is a requirement for ATM activation (Lee and Paull, 2005) . MRN-resected DNA strands are stabilized by RPA enabling the assembly of RAD51 nucleoprotein filaments along single-stranded DNA (Baumann and West, 1997 ). Protruding RAD51 nucleoprotein filaments then facilitate the search for homologous template DNA, and subsequent strand invasion (van Gent et al., 2001) . The following steps involve alignment of homologous DNA sequences, double Holliday junction formation at the point of DNA crossover, and resynthesis of the correct DNA sequence beyond the 3 0 terminus of the invading singlestranded DNA (Giot et al., 1997) . The extended DNA ends are then religated into the original DNA strand, and Holliday junctions are resolved to yield two homologous DNA products (van Gent et al., 2001) . A role for BRCA1 and BRCA2, both of which interact with RAD51 in HRR has also been suggested (Marmorstein et al., 1998) . Consequences of HRR deficiency include an increase in sister-chromatid exchanges and chromosomal aberrations that may lead to aneuploidy (Richardson et al., 2004) . DNA double-strand break repair deficiency syndromes, such as Fanconi Anaemia, are associated with an increased susceptibility to myeloid leukaemia, emphasizing the importance of error-free double-strand break repair in the maintenance of genomic stability and protection against leukaemogenesis.
Using mouse embryonic stem (ES) cells, the aim of this study was to recapitulate predicted early events in alkylator-induced t-AML. Specifically, we aimed to determine whether genetic instability conferred by MMR deficiency is sufficient to deregulate DNA double-strand break repair gene expression, particularly HRR, in ES cell clones. Furthermore, we investigated whether exposure to leukaemogenic DNA-damaging alkylating agents can select stem cell clones with deregulated DNA repair gene expression.
Results

HRR gene expression is deregulated in Msh2-deleted ES cells
The alkylating agent-induced t-AML model predicts that DNA double-strand break repair is directly affected by loss of functional DNA MMR (Casorelli et al., 2003) . MSH2 has been suggested as one possible target in t-AML, although it remains likely that other components of DNA MMR may also be affected, including MLH1 and MSH6. In order to test this hypothesis the expression of eight major DNA doublestrand break repair genes (Brca1, Brca2, Rad51, Rad50, Mre11, Nbn, Ku70 and Ku80) was analysed by real-time quantitative TaqMan PCR in murine ES cells homozygously deleted for Msh2 (Msh2À/À) and compared to expression in wild-type cells (Msh2 þ / þ ) (it should be noted that other MMR-deleted ES cell lines were not available for this study). Gene expression was initially determined in clones derived from untreated Msh2 þ / þ and Msh2À/À ES cells. Clonal cell populations were cultured from single ES cells that formed single colonies when seeded at a mean density of 1 cell per well in 96-well plates. Clonal expansion took an average of 3.5 weeks. Initially, up to 10 independent clones were cultured from single Msh2À/À or Msh2 þ / þ ES cells. This strategy enabled the assessment of gene expression heterogeneity between individual clones.
Median expression of five of the six HRR genes investigated was significantly different between Msh2 þ / þ ES cell clones and Msh2À/À ES cell clones; these were Brca1 (P ¼ 0.004), Brca2 (P ¼ 0.005), Rad51 (P ¼ 0.016), Rad50 (P ¼ 0.03) and Mre11 (P ¼ 0.041) (Figure 1) . Specifically, expression of all five genes was significantly higher in Msh2À/À ES cell clones compared to Msh2 þ / þ wild-type ES cell clones. Furthermore, some Msh2À/À ES cell clones expressed substantially higher levels of the five HRR genes than other clones. In particular, Rad51 expression was up to threefold higher than the median in some Msh2À/À ES cell clones (Figure 1 ). Such 'superexpressing' clones were not a feature of the Msh2 þ / þ ES cell clonal populations investigated (Figure 1) . Nbn, the mouse homologue of the human NBS1 gene, was the only HRR gene investigated that was not expressed at significantly different levels between Msh2 þ / þ and Msh2À/À ES cell clones (P ¼ 0.62).
In contrast to the HRR genes investigated, median expression of the two major NHEJ genes, Ku70 and Ku80, was not significantly different between Msh2 þ / þ and Msh2À/À single-cell-derived ES cell clones (Figure 1) . Similarly, expression of Mlh1 did not differ significantly between Msh2 þ / þ and Msh2À/À ES cell clones.
These data suggest that the HRR pathway is targeted for alteration in Msh2À/À cells. Moreover, the pattern of expression would suggest that HRR genes are consistently overexpressed when Msh2 is deficient. Although overexpression of HRR genes is consistent, the occurrence of superexpressing clones indicate that the level of HRR gene deregulation is variable and substantially higher in some Msh2À/À ES cells than in others.
Homologous recombination DNA repair gene expression is deregulated in cloned wild-type ES cells following treatment with N-methyl-N-nitrosourea (MNU) We next tested whether the phenotype of the Msh2À/À ES cell clones could be recapitulated in MMR-competent wild-type cells by treating with a single dose of the O 6 -guanine methylating agent MNU. Specifically, we tested whether MNU treatment could select for MMR loss and whether the expression of DNA double-strand break repair genes, particularly HRR genes, was deregulated in cell clones derived from an MNU-treated population. MNU is a well-characterized methylating agent originally used as a chemotherapeutic agent, which is also leukaemic in animal model systems (Kawate et al., 1998; Qin et al., 2000) . Furthermore, MNU induces a spectrum of DNA lesions, including O 6 -methylguanine, similar to methylating agents currently used therapeutically (Beranek et al., 1980) . Single-cell derived clones were cultured from ES cells following a single LD 50 dose of MNU. As clinically administered doses of chemotherapeutic alkylating agents result in myelosuppression but not complete bone marrow ablation, this dose was chosen in an attempt to partially recapitulate in vivo toxicity. The LD 50 for MNU was determined by growth inhibition of ES cells following exposure to a range of MNU concentrations (see Materials and methods).
Expression of Msh2 (P ¼ 0.306) and Mlh1 (P ¼ 0.390) was not significantly different between untreated and MNU-treated Msh2 þ / þ ES cell clones ( Figure 2 ). Similarly, expression of Ku70 (P ¼ 0.95) and Ku80 (P ¼ 0.051) was also not significantly different between untreated and MNU-treated clones (Figure 2 ), although the median difference in Ku80 expression approached Figure 1 Relative levels of expression of mouse DNA repair genes in mismatch repair-proficient (Msh2 þ / þ ) and -deficient (Msh2À/ À), single ES cell-derived clones. Each point represents a clone derived from a single ES cell (symbols for clones with similar relative expression levels may overlap); þ / þ refers to Msh2 þ / þ ES cell clones (n ¼ 10, apart from Rad50 and Mlh1 where n ¼ 8); À/À refers to Msh2À/À ES cell clones (n ¼ 9). The mean of each group of clones, and the s.d. for that group are also represented on the graph. Statistically significant (Po0.05) differences in expression (determined by the Mann-Whitney test) are shown in bold.
significance. In contrast, however, three of the six HRR genes investigated demonstrated significant differences in expression when MNU-treated wild-type clones were compared to untreated clones. Specifically, median expression of Rad50 (P ¼ 0.03), Brca1 (P ¼ 0.01) and Brca2 (P ¼ 0.039) was significantly higher in MNUtreated Msh2 þ / þ ES cell clones derived from untreated cells (Figure 2 ). Although median Rad51 expression was not significantly different following MNU treatment, one of the MNU-treated Msh2 þ / þ ES cell clones expressed approximately 6.5-fold higher levels of Rad51 than other clones in the same group ( Figure 2 ). Rad51, Rad50, Brca2 and Brca1 were four of the five HRR genes significantly expressed at higher levels in Msh2À/À ES cell clones in comparison to Msh2 þ / þ ES cell clones.
Gene expression was also investigated in MNUtreated Msh2À/À ES cell clones. However, no differences in expression of the repair genes investigated were observed between MNU-treated and -untreated Msh2À/À ES cell-derived clones (data not shown).
These data suggest that a single dose of MNU to kill 50% of a wild-type ES cell population does not readily select cells deficient in expression of either Mlh1 or Msh2. We cannot, however, exclude the possibility that DNA MMR-deficient cells are generated at low frequency. In contrast, significantly increased expression of three HRR genes and the occurrence of a Rad51 superexpressing clone suggests that a single dose of MNU selects for Msh2 þ / þ cells with a HRR gene expression profile approaching that of the untreated Msh2À/À ES cells.
It remains possible that a single dose of MNU may select for cells with dysfunctional DNA MMR without significant loss of gene expression; perhaps via point mutation, for example. In order to test for dysfunctional DNA MMR in MNU-treated Msh2 þ / þ cell clones, microsatellite instability was assessed at eight independent monomorphic microsatellite markers. Four of the microsatellite markers (D1mit4, D7mit12, D8mit4, D10mit2) are in regions that do not contain apparent coding sequence, whereas the remaining markers were located in the Rad51 locus (D2mit194, D2mit395) or the Brca2 locus (D5Bay1, Brca2). Microsatellite instability was not detected at any of the microsatellite markers analysed in eight representative Msh2 þ / þ wild-type ES cell clones, including four untreated and four MNUtreated cell clones (Table 1; Figure 3 ). In contrast, however, microsatellite instability was widespread in both untreated and MNU-treated ES cell clones derived from Msh2À/À cells (Table 1; Figure 3 ). These data are consistent with the expression data and suggest that loss of functional DNA MMR does not readily occur in wild-type cells following a single LD 50 dose of MNU. As cells were only treated with a single dose of MNU, this is not entirely unexpected. However, the possibility that DNA MMR function may be lost via defects in components other than Msh2 or Mlh1, a mechanism that may not always result in high-grade microsatellite instability (Hatch et al., 2005) , cannot be excluded. Furthermore, should Msh2 þ / þ ES cells have acquired a MMR defect as a result of MNU treatment it is possible that further cell divisions may have been required to reach the level of MSI observed in Msh2À/À ES cell clones.
The presence of a single unstable allelic form at both of the Rad51 markers investigated (D2mit194 and D2mit395) in one of the Msh2À/À ES cell clones (clone 4) suggests that allelic loss may have occurred across the Rad51 locus in this clone; an interesting possibility considering that allelic loss has also been detected in genetic regions close to, or containing Rad51 in mouse models of radiotherapy-induced AML (Clark et al., 1996; Boulton et al., 2003) . Although it is not possible to distinguish allelic loss from biallelic instability in this clone, the lack of apparent homozygosity at Figure 2 Relative levels of expression of mouse DNA repair genes in mismatch repair-proficient (Msh2 þ / þ ) single ES cell-derived clones following treatment with N-methyl-N-nitrosourea (MNU). Each point represents a single ES cell clone (symbols for clones with similar relative expression levels may overlap); ÀMNU refers to untreated Msh2 þ / þ ES cell clones (n ¼ 10, apart from Rad50 and Mlh1 where n ¼ 8); þ MNU refers to MNU-treated Msh2 þ / þ ES cell clones (n ¼ 6). The mean of each group of clones, and the s.d. for that group are also represented on the graph. Statistically significant (Po0.05) differences in expression (determined by the MannWhitney test) are shown in bold.
either of these markers in any of the other Msh2À/À ES cell clones suggests allelic loss as the most likely explanation, and provides further indirect evidence for deregulation of HRR as a consequence of MMR deficiency.
HRR gene expression in haematopoietic cells derived from ES cells
We have established that HRR gene deregulation is a characteristic feature of Msh2-deleted ES cells, and also that a similar HRR gene expression profile can be induced in wild-type ES cells following a single dose of MNU. We next tested whether this deregulated HRR phenotype was maintained in haematopoietic cells differentiated from ES cells. Monocytes can be generated in vitro from ES cells via the formation of embryoid bodies (EBs) (Clarke et al., 2000) . EBs are complex structures that recapitulate primitive haematopoiesis of the mouse embryo (Keller et al., 1993) , the primary stages of which are shown in Figure 4 . Monocytes are extruded from ES cell-derived EBs from approximately day 9 (Figure 4) (Keller et al., 1993) . Monocytes can be reproducibly generated using this system. However, low monocyte numbers and generally lower expression of HRR genes in differentiated cells relative to ES cells (data not shown), limited the amount of expression data that could be generated using this experimental system. As such, the expression of Rad51 only (the most highly expressed HRR gene of those analysed in monocytes), was investigated in Msh2 þ / þ and Msh2À/À EBderived monocytes in order to test whether the expression pattern obtained in ES cells was retained when differentiated to haematopoietic cells. As expected, median Rad51 expression levels were substantially lower in monocytes compared to ES cells ( Figure 5 ), consistent with a previous study by Ramalho-Santos et al. (2002) who reported that expression of genes promoting resistance to cell stress, including DNA repair genes, is higher in stem cells compared to differentiated haematopoietic cells; a phenotype that is presumed to protect against carcinogenesis. Median Rad51 expression levels were marginally higher in monocytes derived from Msh2À/À ES cells compared to monocytes from Msh2 þ / þ ES cells, but not significantly different ( Figure 5 ). However, two of the Msh2À/À monocyte clones expressed very high levels of Rad51 ( Figure 5 ). Indeed, these superexpressing clones expressed 20-and 80-fold higher levels of Rad51 in comparison to the median expression level of the entire Msh2À/À monocyte population. These data are very similar to those observed in ES cell clones, and suggest that the general pattern of Rad51 gene expression, specifically the occurrence of superexpressing clones, is maintained through EB formation during differentiation to haematopoietic cells.
Melphalan treatment selects against cell clones with deregulated HRR Nitrogen mustards such as melphalan and mechlorethamine are used extensively as chemotherapy agents. Like chemotherapeutic methylating agents, nitrogen mustards are also suspected human leukaemogens and are 
+ or À (number), loss or gain of bases at an unstable allele; 0, stable allele.
Deregulation of HRR in stem cell clones LJ Worrillow and JM Allan frequently used in combination chemotherapy with methylating agents. Indeed, it has been suggested that the particular combination of mechlorethamine and procarbazine used to treat Hodgkin's disease is responsible for the leukaemogenicity of the MOPP regimen (Delwail et al., 2002) . Given that nitrogen mustards are efficient crosslinkers of DNA and that we have demonstrated deregulation of HRR gene expression in both Msh2À/À ES cells and monocytes, we determined whether treatment with an interstrand DNA crosslinking agent could select DNA MMR-deficient cells based on HRR efficiency. This was achieved by analysing DNA double-strand break repair gene expression in clones derived from Msh2À/À ES cells following treatment with a LD 50 of melphalan. As with MNU, a cytotoxic dose (LD 50 ) was chosen in an attempt to recapitulate the effects of high-dose chemotherapy on the bone marrow.
Following melphalan treatment of Msh2À/À ES cells and subcloning, expression of four of the six HRR genes investigated was significantly altered; these were Mre11 (P ¼ 0.0172), Brca1 (P ¼ 0.005), Brca2 (P ¼ 0.010) and Rad51 (P ¼ 0.012) (Figure 6 ). The expression of all genes was lower in cell clones treated with melphalan compared to untreated cells. Rad50 expression was also lower in Msh2À/À ES cell clones following melphalan treatment although this result was not significant (P ¼ 0.06). Nbn was the only HRR gene where expression was not affected by melphalan treatment (P ¼ 0.817). Similarly, expression of the NHEJ genes Ku70 (P ¼ 0.23) and Ku80 (P ¼ 0.56), and the Mlh1 (P ¼ 0.51) MMR gene, were not significantly different between Msh2À/À melphalan-treated and -untreated ES cell clones. The low expression levels observed for five of the six HRR genes investigated, the same five genes that were deregulated in Msh2À/À ES cells, suggests that melphalan treatment selects against ES cell clones with deregulated HRR gene expression, including superexpressing clones.
Discussion
The proposed model of DNA MMR-deficient t-AML outlines a disease mechanism by which chemotherapy treatment selects for myeloid stem cell clones deficient in DNA MMR. As O 6 -guanine alkylators mediate cytotoxicity via the DNA MMR system it is likely that exposure to chemotherapeutic O 6 -guanine alkylators, such as procarbazine, dacarbazine or temozolomide, will support the emergence of DNA MMR-deficient myeloid stem cell clones. Indeed, this selection mechanism has been shown in vitro (Hampson et al., 1997; Humbert et al., 1999) . In the present study, however, selection of low or deficient expressers of Msh2 or Mlh1 following treatment with the O 6 -guanine alkylator MNU was not observed. The absence of microsatellite instabilitypositive Msh2 þ / þ ES cell clones after treatment with MNU supports this observation (Table 1 ). It remains possible that MMR-deficient clones may have been present in low frequency among the Msh2 þ / þ population but not detected due to low statistical power of the adopted cloning system.
It is well established that cells deficient in DNA MMR develop a mutator phenotype that can drive genetic changes that may contribute to malignant transformation (Loeb, 2001 ). In t-AML following alkylating chemotherapy exposure, a subset of patients (30-80%) display a mutator phenotype indicated by high levels of microsatellite instability (Ben-Yehuda et al., 1996; Sheikhha et al., 2002; Casorelli et al., 2003; Worrillow et al., 2003) . Other genetic alterations commonly associated with alkylator-related microsatellite unstable t-AML include chromosomal deletions, such as deletion of 5q (Pedersen-Bjergaard et al., 2002) , implicating DNA double-strand breaks in the aetiology of t-AML.
The HRR system is responsible for maintaining chromosomal stability by the accurate repair of DNA 
Msh2À/À ES cell clones (e,f) and MNU-treated Msh2À/À ES cell clones. Stutter bands, identified as declining peak sizes that may occur on either side of a major peak, are also visible. double-strand breaks. One model proposes that DNA MMR directly interacts with HRR to correct single base mismatches between slightly diverged DNA sequences permitting error-free exchange of genetic material (Karran, 2001 ). This loss of DNA MMR may allow error-prone HRR to occur. Alternatively, DNA MMR deficiency may indirectly affect HRR by conferring global genomic instability. In support of this, microsatellite instability within a poly(t) repeat in MRE11, which is predicted to modify exon 5 splicing, has been reported in three of 11 cases of t-AML displaying complex chromosomal abnormalities (Casorelli et al., 2003) . Our data demonstrating microsatellite instability and possible allelic loss at the Rad51 locus in MMRdeficient cells provides further support for this model. Regardless of the mechanism, the data presented in this study demonstrates that HRR gene expression is deregulated in Msh2 null cells; a phenotype that can be partially recapitulated by treatment of wild-type cells with a methylating agent.
Clones derived from melphalan-treated Msh2À/À ES cells expressed significantly lower levels of the majority of HRR genes investigated (Brca1, Brca2, Rad51, Mre11 and Rad50) compared to untreated Msh2À/À ES cell clones. Melphalan selection against cells that express high levels of HRR genes suggests susceptibility to melphalan-induced cytotoxicity. However, this observation is not a predictable outcome when examining the participation of HRR in the removal of melphalaninduced DNA damage. Melphalan is a bifunctional alkylating agent that confers cytotoxicity through formation of DNA interstrand crosslinks. When DNA crosslinks are encountered by the DNA replication machinery, the replication process is stalled. This can cause DNA double-strand breaks which may be repaired via the HRR pathway (Wang et al., 2001) . It would therefore be reasonable to expect an increase in HRR gene expression to promote resistance to melphalan-induced cytotoxicity. However, data from the present study demonstrate that the opposite occurs when Msh2À/À ES cell clones are exposed to melphalan; clones expressing high levels of Mre11, Rad51, Brca2 and Brca1 are actually selected against. This observation is consistent with functional studies investigating the effects of HRR gene deregulation on DNA strand break repair, which have focused primarily on RAD51. Consistent with a role in the pathogenesis of MMR-defective t-AML, RAD51 overexpression reduces the efficiency and fidelity of DNA double-strand breakdirected HRR. A reduced efficiency of HRR is thought to be mediated by an imbalance of RAD51 in the formation of RAD51-protein complexes during HRR (Kim et al., 2001; Richardson et al., 2004) . Indeed, only a twofold increase in RAD51 expression, such as observed in the present study, is sufficient to promote self-complexing of RAD51 (Richardson et al., 2004 ). An imbalance of BRCA1, BRCA2 or RAD51 may therefore deregulate HRR, possibly encouraging an errorprone HRR response. This model is supported by the observation that DNA double-strand break-induced chromosome aberrations can be generated in vitro by increasing cellular RAD51 expression (Richardson et al., 2004) . Furthermore, a concomitant increase in the expression of proteins that associate with RAD51 during HRR, does not counteract this imbalance (Kim et al., 2001) . BRCA1 and BRCA2 interact with RAD51 during HRR, possibly facilitating nuclear translocation, nuclear filament assembly, and realignment of repaired DNA strands. Direct binding of BRCA2 to RAD51 is thought to maintain RAD51 in a monomeric state (Marmorstein et al., 1998 ). An imbalance of BRCA1, BRCA2 or RAD51 may therefore deregulate HRR, possibly encouraging an error-prone HRR response. Taken together, these data suggest that overexpression of key HRR genes destabilizes HRR function, presumably by causing a pathway imbalance. Consistent with the observations reported in this study, there is now considerable evidence that overexpression of proteins involved in other complex DNA repair pathways, such as base excision repair, can also lead to a detrimental imbalance (Glassner et al., 1998; Posnick and Samson, 1999) . Indeed, this mechanism is thought to be responsible for the genomic instability seen in ulcerative colitis (Hofseth et al., 2003) .
In view of these in vitro findings it is interesting to speculate that alkylating chemotherapy may select a highly unstable, DNA MMR-deficient myeloid stem cell clone carrying genetic alterations deregulating HRR (by overexpression of specific HRR genes); a mechanism that may promote erroneous repair of DNA doublestrand breaks. The melphalan selection data presented in this study demonstrates that superexpressers of HRR genes are hypersensitive to the cytotoxic effects of DNA interstrand crosslinking agents, suggesting that survival of HRR-deregulated cells may depend on the accumulation of genetic alterations affecting other cell pathways, including cell death, for example. In the MMR-deficient t-AML model it is feasible that MMR-deficient clones may acquire additional mutations that not only destabilize HRR but also promote clonal survival.
Although we did not find any significant differences in expression of Ku70 or Ku80 between Msh2À/À ES and Msh2 þ / þ ES cell clones, or after alkylating agent treatment, we cannot exclude the possibility that deregulation of the NHEJ pathway is involved in the pathogenesis of t-AML. Indeed, nuclear extracts from Figure 6 Relative levels of expression of mouse DNA repair genes in mismatch repair-deficient (Msh2À/À) single ES cell-derived clones following treatment with melphalan. Each point represents a single ES cell subclone (symbols for clones with similar relative expression levels may overlap); Àmelp. refers to untreated Msh2À/À ES cell clones (n ¼ 8), and þ melp. refers to melphalan-treated Msh2À/À ES cell clones (n ¼ 8). The mean of each group of clones, and the s.d. for that group are also represented on the graph. Statistically significant (Po0.05) differences in expression (determined by the Mann-Whitney test) are shown in bold.
myeloid leukaemia cell lines and de novo myeloid leukaemic blast cells show an increased frequency of DNA double-strand break misrepair (Gaymes et al., 2002) . Moreover, inhibition of Ku80 or Ku70 restored double-strand break repair fidelity, suggesting that overactivity of these proteins in myeloid blast cells was responsible for the increased frequency of misrepair. Although we observed a borderline significant increase in Ku80 expression in wild-type ES cell clones following MNU treatment a more exhaustive study would be required to determine whether or not dysfunctional NHEJ plays a major role in t-AML pathogenesis.
In summary, we have demonstrated that HRR gene expression is deregulated as a consequence of DNA MMR loss. This HRR gene expression phenotype can be partially recapitulated in wild-type cells by treatment with a methylating agent, and is also maintained when ES cells are differentiated to monocytes. Negative selection of HRR gene overexpressing ES cell clones by melphalan treatment suggests that additional genetic alterations may be required in order to promote clonal survival. Taken together, these data suggest a model of t-AML whereby deregulation of HRR occurs as a consequence of DNA MMR loss or exposure to methylating agents, which is predicted to ultimately contribute to chromosomal instability and leukaemogenesis.
Materials and methods
Maintenance of ES cells
Msh2 þ / þ and Msh2À/À ES cells (129/Ola genetic background) adapted for growth on gelatinized tissue culture surfaces were a kind gift from Professor Hein te Riele (Netherlands Cancer Institute, Amsterdam, The Netherlands). Both copies of Msh2 had previously been deleted using the gene-targeting method described by de Wind et al. (1995) . Msh2À/À ES cells are tolerant to the killing effects of methylating agents, and also display some microsatellite instability (de Wind et al., 1995) .
Undifferentiated ES cells were routinely maintained on tissue culture flasks (pretreated with 0.1% gelatin in tissue culture grade water; Stem Cell Technologies) under appropriate conditions (5% CO 2 , 371C), in Dulbecco's modified Eagle medium (DMEM; Invitrogen) supplemented with 3% leukaemia inhibitory factor-conditioned media (LIF-CM) together with 15% serum replacement media (Invitrogen), 100 U of penicillin, 100 mg of streptomycin, 2 mM of Lglutamine, 0.1 mM of nonessential amino acids, and 100 mM of monothioglycerol (Sigma). LIF-CM was generated from Chinese hamster ovary cells transfected with a LIF expression vector (a gift from Professor Constance Bonifer, Molecular Medicine Unit, University of Leeds). ES cells were passaged onto fresh gelatinized plates every 2 days when approximately 80% confluent and showing no signs of differentiation.
Treatment of ES cells with MNU or melphalan
Msh2 þ / þ and Msh2À/À ES cells at 60-80% confluency were trypsinized and washed twice in 1 Â PBS to remove all traces of maintenance media. ES cells, at a density of 2 Â 10 5 cells/ml in DMEM, were exposed to a single dose of MNU (0.5 mM to kill 50% of Msh2À/À ES cells, or 0.25 mM to kill 50% of Msh2 þ / þ ES cells), melphalan (2.5 mM to kill 50% of Msh2À/À ES cells), or diluent alone (DMEM), for 1 h at 371C. The dose of melphalan or MNU required to kill 50% of the ES cell population was predetermined using a growth inhibition assay. This involved exposure of ES cells to serial dilutions of MNU (upto 4 mM) or melphalan (upto 20 mM) for 1 h at 371C, and determining the number of viable ES cells following MNU or melphalan treatment in comparison to an untreated control 6 days later. ES cells were then washed twice in ES cell maintenance media to remove traces of alkylating agent. Treated ES cells were allowed to recover in ES cell maintenance media for 6 days before preparation of single-cell ES cell colonies, or differentiation to EBs.
Preparation of single-cell-derived ES cell colonies
In all, 60-80% subconfluent ES cells were trypsinized and viable cell numbers were determined by averaging at least two cell counts, using the Trypan blue dye exclusion method. ES cells were then seeded at an average density of one cell per well in a gelatinized 96-well tissue culture grade plate (Nunc), and cultured in ES cell maintenance media until colonies were visible. ES cells were transferred from wells containing a single ES cell colony to six-well gelatinized tissue culture grade plates (Nunc) following trypsinization, and grown to 80% confluency. Subconfluent ES cell clones cultured from single colonies were then harvested during exponential growth phase by trypsinization. Trypsinized ES cells were washed twice in 1 Â PBS to remove traces of media. RNA was then extracted from half of the population using the RNeasy mini-kit (Qiagen), and DNA was extracted from an equal number of ES cells using the DNeasy mini-kit (Qiagen), following manufacturer's instructions. Overall, the time taken to culture enough cells for nucleic acid extraction following treatment was approximately 3.5 weeks.
Differentiation of ES cells to EBs and monocytes
ES cells were passaged once in maintenance media replacing DMEM with IMDM. Subconfluent (60%) ES cells were trypsinized and washed twice in IMDM (Invitrogen) to remove traces of LIF, a factor that inhibits differentiation of ES cells. Cells were then resuspended in a volume of IMDM supplemented with 10% differentiation quality FBS (Stem Cell Technologies) to give 3.5 Â 10 2 ES cells when diluted in 2 ml of methylcellulose (Stem Cell Technologies) supplemented with 200 mM of L-glutamine, 150 mM of monothioglycerol, and 4 mg of murine recombinant stem cell factor (Sigma). Suspensions (2 ml) were then aliquoted into bacterial grade 50 mm Petri dishes, and incubated at 371C (95% humidity, 5% CO 2 ). At day 14, monocytes surrounding EBs were collected using a sterile pipette and washed once in 1 Â PBS. A proportion of the clones picked were used for morphological identification of monocytes following the production of Giemsa-stained cytospin preparations.
Preparation of cDNA from total RNA derived from single ES cell-derived clones Complementary DNA was prepared from total RNA extracts and total mouse embryonic RNA (Ambion) using standard procedures. In brief, an equal volume of reverse transcription mastermix (19 mM DTT, 1.9 mM of each dNTP, 2.5 mg random hexamers, and 1.9 Â SuperScriptt buffer in molecular grade water) was added to denatured RNA extracts or a water blank, together with 200 U of Superscriptt Reverse Transcriptase (Invitrogen). Samples were incubated at 371C for 2 h, followed by 10 min at 651C.
Preparation of cDNA from monocytes cDNA was prepared using a method based on the cells-tocDNA kit protocol (Ambion) and the method previously described by Liss (2002) . This involved resuspension of EBderived monocytes in 50 ml of ice-cold cell lysis buffer II (Ambion) and then immediate heating to 751C for 10 min, before cooling on ice for 1 min to inactivate contaminating RNAses. DNase (Ambion) was then added to each sample to give a final concentration of 0.04 U/ml, and incubated for 15 min at 371C to degrade genomic DNA. Inactivation of DNase I was achieved by incubation at 751C for 5 min. cDNA was then prepared from cell lysates using the method previously described for ES cell clones. In order to precipitate cDNA synthesized by reverse transcription, an equal volume of precipitation mastermix made up of 5 ng poly(dC) (Amersham Biosciences), 5 ng polyC (Amersham Biosciences), 20 ng glycogen (Ambion), and 0.2 M sodium acetate (pH 4.0) in a final volume made up to 20 ml with molecular grade water, was added to the cell lysis suspension before vortexing. In all, 150 ml of ethanol (99%v/v in molecular grade water) was then added and samples were mixed thoroughly before incubating overnight at À201C. Nucleic acids were pelleted by centrifugation at 14 000 r.p.m. for 1 h at 41C. The supernatant was removed and cell pellets were carefully washed in ethanol (75%v/v in molecular grade water) before heating up to 451C for 15 min to remove excess ethanol. Pellets were then resuspended in 30 ml molecular grade water (the minimum amount required for TaqMan real-time quantitative-PCR (RQ-PCR)), and stored at À201C. Prior to TaqMan RQ-PCR, samples were heated to 451C for 60 min to ensure cDNA was fully dissolved.
Analysis of repair gene expression using TaqMan RQ-PCR Compatible forward and reverse primers (synthesized by Invitrogen) and TaqMan probes (synthesized by Applied Biosystems) were predicted using the ABI Primer Expresst software (version 1.5, Applied Biosystems) to Brca1, Brca2, Rad51, Rad50, Mre11, Nbn, Ku70, Ku80, Msh2, Mlh1 and the internal reference gene Gus (Table 2) . Test samples were amplified using a standard PCR technique, by Amplitaq Gold (Perkin-Elmer) and forward and reverse primers for each gene, at an annealing temperature of 601C. PCR products were then electrophoresed on 2% agarose gels alongside a base pair ladder to show that uncontaminated products of sufficient quality and yielding one amplification product were present. Standards and samples were analysed in triplicate by TaqMan RQ-PCR. To triplicate wells of an optical 96-well plate test sample cDNA, nontemplate control, or known concentrations of standard cDNA (a doubling dilution series prepared from 50 ng of total RNA reverse transcribed to cDNA) together with optimized concentrations of forward and reverse primers and TaqMan probe, and 1 Â Universal TaqMan mastermix (Applied Biosystems) made up to 20 ml with molecular grade water were added. Plates were pulse centrifuged, and run on an ABI Prismt 7700 sequence detector (Applied Biosystems) under the following thermocycle conditions: cycle 1, 951C for 10 min; cycle 2-41, 951C for 15 s followed by 1 min at 601C. Reactions were analysed using ABI Prismt 7700 software (Applied Biosystems), and standard curves were generated by plotting the log of known standard concentrations against the cycle number determined at the threshold. Relative amounts of gene expression from each target (including the Gus housekeeping gene), were determined from the standard curve for that target set up on the same plate. As more than one plate was required for each target, the same standard dilutions were used to create a curve on each plate. To ensure reproducibility and accuracy, only standard curves with a slope of À3.3 (710%) and a coefficient of variation X0.98 were acceptable. Finally, in order to compare gene expression between samples, data were normalized by dividing the relative amount of test gene expression by the relative amount of internal reference gene (Gus) expression from the same sample. Expression of all 12 genes was analysed in ES cell populations derived from single cells. Only Rad51 and Gus expression were analysed in EB-derived monocytes.
Statistical analysis of gene expression
The relative expression levels among each test group were not normally distributed. The nonparametric Mann-Whitney test was therefore used to compare relative expression of each test gene between Msh2 þ / þ and Msh2À/À ES cell clones, and untreated and treated ES cell clones. Relative expression of Rad51 in Msh2 þ / þ and Msh2À/À EB-derived monocytes was also compared using the Mann-Whitney test. As the Mann-Whitney test is based on the median value, median expression levels have been described in the text of the results section. However, Figures 1, 2, 5 and 6 display mean expression levels so that s.d. calculated from the mean can be included as an indication of spread.
Determination of microsatellite instability in mouse DNA repair genes Microsatellite instability was analysed in two microsatellite markers at the Rad51 locus (D2mit194 and D2mit395), two markers at the Brca2 locus (Brca2 and D5Bay1) and at four (Lowsky et al., 2000) . Primer sequences for all markers were obtained from the National Centre for Biotechnology Information website (www.ncbi.nlm.nih.gov).
Microsatellite instability was analysed in genomic DNA extracted from 16 representative single-cell-derived ES cell clones (i.e. four single-cell-derived ES clones from each of the following groups; DNA MMR-proficient clones and MMRdeficient clones untreated or treated with MNU) using 5 0 dyelabelled forward and -unlabelled reverse primers (Proligo). PCR amplification was set up by the addition of approximately 50 ng of template DNA, 10 pmoles of forward and reverse primer, 10 mM of each dNTP, 15 mM of Mg 2 þ and 0.1 U of Thermoprime DNA polymerase in 1 Â Thermoprime PCR buffer (ABgene) diluted in 20 ml molecular grade water. Amplification was carried out using the following thermocycle conditions: cycle 1, 941C for 1 min; cycles 2-37, 941C for 30 s, 551C for 30 s, and 721C for 30 s; cycle 38, 721C for 7 min. To confirm that amplification was successful, 5 ml of PCR product was electrophoresed on a 2% agarose gel alongside a 100 bp ladder. The remaining PCR product was added to 5 ng of glycogen (Ambion), 1.5 ml of 3 M sodium acetate (pH5.2), and 50 ml of ethanol (95%v/v in molecular grade water) before precipitating by incubation overnight at À201C. Precipitates were then pelleted in a microfuge at 41C for 30 min (14 000 r.p.m.). Each pellet was washed in ethanol (70%v/v in molecular grade water) and then dried in a thermocycler at 451C for 30 min before reconstitution in an appropriate volume of CEQt sample loading solution (Beckman Coultier) together with the CEQt 400 bp ladder (Beckman Coultier). Reconstituted samples were then run on the CEQt Gene Analysis System (Beckman Coultier) and analysed using the CEQt8000 Fragment Analysis software, (version 8), in accordance with manufacturer's instructions. As the mouse ES cells used in this study did not originate from a crossbreed, it was unlikely that the microsatellite markers analysed in ES cell clones would be polymorphic. The major peak identified in MMR-proficient clones was presumed to be the stable allele, and the appearance of smaller peaks 2 or 4 bp either side of this peak were presumed to be stutter bands (artefacts introduced as a result of DNA polymerase slippage during PCR amplification). Microsatellite instability was identified as a major peak differing in base pair size to the stable alleles visualized in MMR-proficient clones.
